What is an ED combo treatment? Evidence and questions to ask
Advertisements for ED combinations can promise more than the evidence for a particular preparation establishes. Start with what is in the product, whether it is FDA-approved and what evidence supports the exact proposed use.
An ED combination contains more than one active ingredient. A compounded preparation is not FDA-approved. A sublingual troche dissolves in the mouth, but its format does not establish faster action or equivalent safety and effectiveness.
- What a "combo" actually is, and what a 503A compounding pharmacy is allowed to make
- Why approval of an ingredient does not approve a compounded combination
- Why a plausible mechanism does not prove a treatment benefit
- What a sublingual troche is and what its format cannot establish
A combo is a custom preparation, not a stronger version of the pill
Some ingredients used in compounded ED preparations also occur in FDA-approved medicines. That does not mean each ingredient is approved for ED or for the proposed route, or that the combination has been reviewed by FDA.
A compounded preparation is distinct from an FDA-approved finished drug. A patient-specific prescription does not itself establish every compounding requirement.
Start with the word that does the heavy lifting: compounded. A 503A compounding pharmacy is a state-licensed pharmacy that prepares a medication for a specific patient, based on a specific prescription, when a commercially available product does not fit that person's needs. The FDA describes 503A compounding as the practice of combining, mixing, or altering ingredients to create a tailored medication for an individual patient.
What a sublingual troche changes (and what it does not)
| Approved PDE5 drug | Other format or device | Compounded preparation | |
|---|---|---|---|
| What it is | An approved PDE5 drug product | Product-specific: a drug film or a non-medicated device gel | A compounded preparation |
| Evidence for combining mechanisms | Assess the approved product | Assess the exact product | A plausible mechanism does not establish safety or added benefit |
| Format | Swallowed tablet | Dissolvable film or topical gel | Sublingual troche or chewable |
| FDA status | Check the specific approved drug | Depends on the product; Eroxon is a device | Not FDA-approved |
| Prescription needed? | Yes | Pill yes; OTC gel no | Yes, patient-specific |
| Who decides it fits | A clinician | A clinician (or self, for OTC gel) | A clinician, with your history |
A sublingual troche is designed to dissolve in the mouth. Its absorption and clinical effects depend on the exact ingredients and formulation. A compounded troche is not FDA-approved, and a different format does not establish faster action or equivalent safety and effectiveness.
And it is still a compounded, prescription-only preparation. The convenient format does not change the rules. A clinician still evaluates first, and a licensed pharmacy still prepares it to your specific prescription.
How to tell a real combo option from a sales pitch
Honest framing. A trustworthy provider tells you plainly that a combo is a compounded, patient-specific preparation, not an FDA-approved finished drug and not a generic. If a site calls it a brand equivalent, be skeptical.
A prescribing evaluation does not prove a compounded combination’s safety or effectiveness. Cialis labeling says combinations with other PDE5 inhibitors or ED therapies have not been studied and instructs patients not to combine PDE5 inhibitors. Discuss approved treatment options and the evidence for any proposed alternative with a clinician.
Your next three steps
Explore your ED treatment options
- Online evaluation by a licensed clinician
- Treatment based on your health and goals
- Clear pricing before you commit
From price shown is the 12-month plan rate. Prices may vary.
Frequently asked questions
Was this helpful?
Keep reading
Men's Health
Men's Health
Men's Health
Men's Health
Men's Health
Men's Health
Sources
- U.S. Food and Drug Administration. "Compounding and the FDA: Questions and Answers." (accessed June 5, 2026). fda.gov
- FDA. Human Drug Compounding Policies and Rules. Accessed September 14, 2026. fda.gov
- StatPearls / NCBI Bookshelf. "Erectile Dysfunction." (accessed June 5, 2026). ncbi.nlm.nih.gov
- StatPearls / NCBI Bookshelf. "Phosphodiesterase 5 (PDE5) Inhibitors." (accessed June 5, 2026). ncbi.nlm.nih.gov
- American Urological Association. "Erectile Dysfunction: AUA Guideline." (accessed June 5, 2026). auanet.org
- Cleveland Clinic. "Erectile Dysfunction: Causes, Symptoms and Treatment." (accessed June 5, 2026). my.clevelandclinic.org
- Federal Trade Commission. "Rule Concerning Recurring Subscriptions and Other Negative Option Programs." (accessed June 5, 2026). ftc.gov
- [Primary source]( pi.lilly.com
- [Primary source]( accessdata.fda.gov